These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Effect of ligustrazine on proliferative glomerulonephritis].
    Author: Tang X.
    Journal: Zhong Yao Cai; 2003 Aug; 26(8):611-2. PubMed ID: 14649206.
    Abstract:
    OBJECTIVE: To investigate the therapeutic effect of ligustrazine on proliferative nephritis. METHODS: 45 patients with mesangial cell proliferation were randomly divided into two groups according to age, clinical manifestations and the pathological lesions. Steroid, cyclophosphamide, losartan and dipyridamole were given to 20 patients in the control group. Ligustrazine with the dosage of 80 mg twice a day was given to 25 patients in the treatment group by intravenous perfusion besides the medicine used in the control group. The course of ligustrazine treatment lasted three weeks. RESULT: The proteinuria and hematuria were decreased significantly with the increases of urine volume, serum albumin and creatinine clearance after ligustrazine treatment. The improvement of serum albumin, proteinuria and hematuria in the treated group were significant compared with control group after treatment. CONCLUSION: Ligustrazine is eutherapeutic in treating proliferative glomerulonephritis, with the less risk of hemorrhage, ligustrazine can be used for long-term treatment without special monitored.
    [Abstract] [Full Text] [Related] [New Search]